Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Mexiletine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A known ✓ | Q14524 | 3/20 | 1.00 |
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 1.00 |
| ▸ | SCN9A known ✓ | Q15858 | 2/20 | 1.00 |
| ▸ | SCN4A known ✓ | P35499 | 10/20 | 0.96 |
| ▸ | SCN7A known ✓ | Q01118 | 1/20 | 0.96 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.96 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.96 |
| ▸ | SCN11A known ✓ | Q9UI33 | 1/20 | 0.96 |
| ▸ | SCN8A known ✓ | Q9UQD0 | 1/20 | 0.96 |
| ▸ | SCN10A known ✓ | Q9Y5Y9 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.96 |
| ▸ | TSHR | P16473 | 2/20 | 0.96 |
| ▸ | MAOA | P21397 | 2/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.96 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.96 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mexiletine SCHEMBL6521444 | 1.00 | SCN5A (1.00) | SCN5ALMNASCN1ASCN9ASCN4A | |
| (S)-Mexiletine SCHEMBL3645798 | 1.00 | SCN5A (1.00) | SCN5ALMNASCN1ASCN9ASCN4A | |
| Mexiletine SCHEMBL42226 | 1.00 | SCN5A (1.00) | SCN5ALMNASCN1ASCN9ASCN4A | |
| (R)-Mexiletine SCHEMBL29366590 | 1.00 | SCN5A (1.00) | SCN5ALMNASCN1ASCN9ASCN4A | |
| (S)-Mexiletine SCHEMBL13046569 | 0.98 | SCN4A (1.00) | SCN5ALMNASCN1ASCN9ASCN4A | |
| (R)-Mexiletine SCHEMBL16082 | 0.98 | SCN4A (1.00) | SCN5ALMNASCN1ASCN9ASCN4A | |
| Mexiletine SCHEMBL8858385 | 0.98 | SCN4A (1.00) | SCN5ALMNASCN1ASCN9ASCN4A | |
| Mexiletine SCHEMBL16081 | 0.98 | SCN4A (1.00) | SCN5ALMNASCN1ASCN9ASCN4A | |
| Mexiletine SCHEMBL1652207 | 0.94 | SCN4A (0.92) | SCN5ALMNASCN1ASCN9ASCN4A | |
| Mexiletine SCHEMBL8819167 | 0.88 | SCN4A (0.80) | SCN5ALMNASCN1ASCN9ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137065-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | Pharnext (FR) | 2017-03-08 | — | — | EP | disclosed |
| WO-2015165948-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2015-11-05 | — | — | WO | disclosed |
| EP-2560631-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | Pharnext (FR) | 2013-02-27 | — | — | EP | disclosed |
| WO-2012117076-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | PHARNEXT (FR) | 2012-09-07 | — | — | WO | disclosed |
| WO-2004014841-A1 | COMPOUNDS, PRO-DRUGS AND CONJUGATES DERIVED FROM MEXILETINE | SIRUS PHARMACEUTICALS LTD (GB) | 2004-02-19 | — | — | WO | disclosed |